Should eGFR and albuminuria be added to the framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction

Nephron - Clinical Practice

Volumn 119, Issue 2, 2011, Pages

  Chang, Alex ^a   Kramer, Holly ^a,b  

^a Department of Medicine   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Creatinine; Cystatin C; Risk prediction

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DISEASE ASSOCIATION; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CREATININE; FORECASTING; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 79960850406     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000325669     Document Type: Review

References (56)

1. Coresh J, Selvin E, Stevens LA, et al: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. Shlipak MG, Fried LF, Cushman M, et al: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745.
3. Shlipak MG, Simon JA, Grady D, et al: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38: 705-711. (Pubitemid 32835740)
4. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753. (Pubitemid 34183941)
5. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065. (Pubitemid 37413751)
6. Weiner DE, Krassilnikova M, Tighiouart H, Salem DN, Levey AS, Sarnak MJ: CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: A cohort study. BMC Nephrol 2009; 10: 26.
7. Manjunath G, Tighiouart H, Coresh J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-1129. (Pubitemid 36315592)
8. Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55. (Pubitemid 36044403)
9. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS: Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 102: 47-53.
10. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J: Association of kidney function and albuminuria with cardiovascular mortality in older vs. younger individuals: The HUNT II study. Arch Intern Med 2007; 167: 2490-2496. (Pubitemid 350254909)
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
12. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
13. Warnock DG, Muntner P, McCullough PA, et al: Kidney function, albuminuria, and allcause mortality in the REGARDS (reasons for geographic and racial differences in stroke) study. Am J Kidney Dis 2010; 56: 861-871.
14. Arnlov J, Evans JC, Meigs JB, et al: Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005; 112: 969-975. (Pubitemid 41170264)
15. Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-426. (Pubitemid 32681484)
16. Hemmelgarn BR, Manns BJ, Lloyd A, et al: Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
17. Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ: Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis 2009; 207: 534-540.
18. D'Agostino RBS, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187. (Pubitemid 32640849)
19. Lloyd-Jones DM, Liu K, Tian L, Greenland P: Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006; 145: 35-42. (Pubitemid 46780605)
20. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847. (Pubitemid 28213628)
21. Anderson RJ, O'brien M, MaWhinney S, et al: Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA cooperative study #5. Kidney Int 1999; 55: 1057-1062. (Pubitemid 29100719)
22. Beddhu S, Allen-Brady K, Cheung AK, et al: Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002; 62: 1776-1783. (Pubitemid 35286286)
23. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636. (Pubitemid 32322240)
24. Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315. (Pubitemid 38526012)
25. National kidney foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39:S46-S64.
26. Kramer H, Jacobs DR, Jr, Bild D, et al: Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43.
27. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
28. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354. (Pubitemid 26075843)
29. Go AS, Yang J, Ackerson LM, et al: Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study. Circulation 2006; 113: 2713-2723. (Pubitemid 43947989)
30. Gutierrez OM, Januzzi JL, Isakova T, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
31. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH: Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2009; 14: 240-246.
32. Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013. (Pubitemid 47530570)
33. Smith DH, Johnson ES, Thorp ML, Petrik A, Yang X, Blough DK: Outcomes predicted by phosphorous in chronic kidney disease: A retrospective CKD-inception cohort study. Nephrol Dial Transplant 2010; 25: 166-174.
34. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979; 110: 281-290. (Pubitemid 10204328)
35. Coresh J, Byrd-Holt D, Astor BC, et al: Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188. (Pubitemid 43073171)
36. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-3421.
37. National Kidney Foundation: K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41(suppl 3):S1-S152.
38. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P: The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49: 37-45. (Pubitemid 44932194)
39. Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR: Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006; 48: 1183-1189. (Pubitemid 44345124)
40. Wang TJ, Gona P, Larson MG, et al: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639. (Pubitemid 44969122)
41. Zethelius B, Berglund L, Sundstrom J, et al: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116. (Pubitemid 351679597)
42. Kim HC, Greenland P, Rossouw JE, et al: Multimarker prediction of coronary heart disease risk: The Women's Health Initiative. J Am Coll Cardiol 2010; 55: 2080-2091.
43. Steyerberg EW, Vickers AJ, Cook NR, et al: Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology 2010; 21: 128-138.
44. Pencina MJ, D'Agostino RB S, D'Agostino RB, Jr, Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-212. (Pubitemid 351193639)
45. Lloyd-Jones DM, Tian L: Predicting cardiovascular risk: So what do we do now? Arch Intern Med 2006; 166: 1342-1344. (Pubitemid 44036344)
46. Weiner DE, Tighiouart H, Elsayed EF, et al: The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50: 217-224. (Pubitemid 47031564)
47. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA: Biomarkers to predict recurrent cardiovascular disease: The Heart and Soul study. Am J Med 2008; 121: 50-57.
48. Ito H, Pacold I, Durazo R, et al: The effect of including cystatin C or creatinine in cardiovascular risk model for asymptomatic individuals. The Multi-Ethnic Study of Atherosclerosis. Circulation 2010; 122:A8982.
49. De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004; 173: 381-391.
50. Weiner DE, Tighiouart H, Griffith JL, et al: Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med 2007; 120: 552.e1-552.e8.
51. Keller C, Katz R, Cushman M, Fried LF, Shlipak M: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008; 9: 9.
52. Knight EL, Verhave JC, Spiegelman D, et al: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421. (Pubitemid 38406982)
53. Folsom AR, Kronmal RA, Detrano RC, et al: Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008; 168: 1333-1339. (Pubitemid 351930841)
54. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004; 291: 210-215. (Pubitemid 38082815)
55. Polonsky TS, McClelland RL, Jorgensen NW, et al: Coronary artery calcium score and risk c lassification for coronary heart disease prediction. JAMA 2010; 303: 1610-1616.
56. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR: N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28:1374-1381. (Pubitemid 47355969)